StockStory Backs GMED and RBA, Flags DOCU as Avoid

StockStory on June 5, 2026, issued positive ratings on Globus Medical (NYSE:GMED) and RB Global (NYSE:RBA) while advising investors to avoid DocuSign (NASDAQ:DOCU), citing stretched valuation. Globus Medical, with a $10.86 billion market cap, trades at $80.75 per share, or 16.2x forward P/E. The medical-device company, which launched over 10 new products in 2023, benefits from a diversified spine and orthopedic portfolio across 64 countries. RB Global, valued at $19.66 billion, trades at $105.53 with a 22.2x forward P/E, supported by its global marketplace for commercial assets. DocuSign, a $9.90 billion agreement-management platform, trades at $48.52, or 2.9x forward price-to-sales. StockStory flagged the valuation as unattractive relative to its mid-cap peers, advising investors to steer clear.